The aryl hydrocarbon receptor (AHR) has physiological roles in the absence of exposure to exogenous ligands and mediates adaptive and toxic responses to the environmental pollutant, 2,3,7,. A readily metabolized AHR agonist, 3-methylcholanthrene, disrupts expression of mouse hepatic growth hormone (GH) signaling components and suppresses cytochrome P450 2D9 (Cyp2d9), a male-specific gene controlled by pulsatile GH via signal transducer and activator of transcription 5b (STAT5b). Using TCDD as an essentially non-metabolized AHR agonist and Ahr -/-mice as the preferred model to determine the AHR-dependence of biological responses, we now show that two mouse hepatic STAT5b target genes, Cyp2d9 and major urinary protein 2 (Mup2), are suppressed by TCDD in an AHRdependent manner. TCDD also decreased hepatic mRNA levels for GH receptor, Janus kinase 2, and STAT5a/b with AHR-dependence. Without inducing selected hepatic inflammatory markers, TCDD caused AHR-dependent induction of Cyp1a1 and NADPH-cytochrome P450 oxidoreductase (Por) and suppression of Cyp3a11. In vehicle-treated mice, basal mRNA levels for CYP2D9, CYP3A11, POR, serum amyloid protein P, and MUP2 were influenced by Ahr genetic status. We conclude that AHR activation per se leads to dysregulation of hepatic GH signaling components and suppression of some, but not all, STAT5b target genes.
Introduction
The aryl hydrocarbon receptor (AHR) mediates both adaptive and toxic effects of halogenated aromatic hydrocarbons (HAHs) such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and polycyclic aromatic hydrocarbons (PAHs) such as benzo [a] pyrene and 3-methylcholanthrene (MC) . The adaptive response to AHR agonists is typified by induction of a battery of drug-metabolizing enzymes including cytochrome P450 1A1 (CYP1A1) (Whitlock 1999) . Persistent AHR activation by long-lived pollutants such as TCDD results in toxicities including a wasting syndrome, endocrine disruption, thymic atrophy, chloracne, tumor promotion, teratogenesis, and hepatotoxicity (Poland and Knutson 1982; Pohjanvirta and Tuomisto 1994) . Mice homozygous for an Ahr-null allele (Ahr -/-mice) are not only extremely resistant to the adaptive and toxic effects of HAH and PAH exposure (Fernandez-Salguero et al. 1996; Shimizu et al. 2000) , but they also display important deficits in hepatic, vascular, and hematopoietic development in the apparent absence of exposure to exogenous AHR ligands Lahvis et al. 2000) . This suggests that endogenous AHR activators play key roles in mammalian physiology and development (Denison and Nagy 2003; Nguyen and Bradfield 2008) .
Although the induction of CYP1A1 is a well-characterized response to HAHs and PAHs, our recent focus has been on the poorly understood processes involved in the suppression of gene expression in response to these chemicals (Riddick et al. 2003; Riddick et al. 2004) . CYP2C11
is the most abundant constitutive hepatic P450 in male rats and a primary physiological regulator of its expression is the pulsatile pattern of pituitary growth hormone (GH) secretion, with signal transducer and activator of transcription 5b (STAT5b) as an intracellular messenger at least partially responsible for the sexually dimorphic expression (Park and Waxman 2001; Ahluwalia et al. 2004; Clodfelter et al. 2006) . Aromatic hydrocarbons cause CYP2C11 down-regulation via a transcriptional mechanism in male rats in vivo (Jones and Riddick 1996; Lee and Riddick 2000) and in cultured primary rat hepatocytes (Safa et al. 1997; Bhathena et al. 2002) . AHR involvement in this suppression response was suggested by structure-activity relationship data (Safa et al. 1997 ) and we showed that the activated AHR binds to a putative dioxin-responsive element (DRE) in the CYP2C11 5'-flanking region (Bhathena et al. 2002) . MC treatment causes down-regulation of luciferase reporter constructs driven by the CYP2C11 promoter and 5'-flanking region when delivered to the liver of living male rats via high-volume tail vein injection (Sawaya and Riddick 2008b) , but no suppression of these reporter plasmids in response to MC or TCDD is observed in transfected continuous cell lines or primary rat hepatocytes (Bhathena et al. 2002; Sawaya and Riddick 2008a) . Although MC interferes with the ability of GH to stimulate hepatic CYP2C11 expression in the liver of hypophysectomized male rats (Timsit and Riddick   2000) , there were no apparent effects of MC on GH-stimulated STAT5b signaling in rat liver or in H4IIE rat hepatoma cells (Timsit and Riddick 2002) .
Mouse Cyp2d9 encodes a male-specific steroid 16α-hydroxylase and the hepatic expression of this gene is clearly regulated by pulsatile GH in a STAT5b-dependent manner (Udy et al. 1997; Davey et al. 1999; Clodfelter et al. 2006) . Similar to the suppression of rat CYP2C11 by aromatic hydrocarbons, we showed that MC treatment of male mice caused downregulation of hepatic Cyp2d9 at the mRNA, protein and catalytic activity levels (Lee et al. 2006) , and this was accompanied by decreased mRNA levels for the GH receptor (GHR) and major urinary protein 2 (MUP2), a GH-regulated and STAT5b-dependent transcript. Others have
shown that treatment of mice with MC leads to an AHR-dependent decrease in hepatic levels of mRNA encoding GHR, Janus kinase 2 (JAK2) and two distinct STAT5b targets, MUP2 and cytokine-inducible Src homology 2 domain-containing protein (CIS) (Nukaya et al. 2004) .
Most previous studies suggesting that aromatic hydrocarbons suppress the expression of sexually dimorphic constitutive hepatic P450s in rats and mice by disrupting the GHR-JAK2-STAT5b signaling pathway were conducted with MC as a prototypical PAH. The parent MC molecule binds AHR with relatively high affinity (Riddick et al. 1994 ) and alters expression of numerous AHR target genes (Kondraganti et al. 2005; Pansoy et al. 2010) ; however, studies with MC are complicated by time-dependent changes in biological potency caused by its rapid biotransformation to multiple metabolites (Poland and Glover 1974; Riddick et al. 1994) , some of which are highly reactive and toxic (Mathieu et al. 2001) . In contrast, TCDD is highly resistant to biotransformation and causes persistent AHR activation without being converted to reactive metabolites in the process, providing an opportunity for a cleaner assessment of the importance of AHR activation per se in a given biological response.
Using TCDD as an essentially non-metabolized AHR agonist and Ahr -/-mice as the preferred model to determine the AHR-dependence of biological responses, our goal was to answer the following questions with respect to levels of hepatic mRNAs encoding selected constitutive hepatic P450s, GH signaling components and STAT5b target genes. 
Statistical analysis
All data are expressed as mean ± SD. All statistical analyses were performed on the original raw data and not on the percent control data presented in the figures. Data were analyzed initially using a randomized-design two-way ANOVA to identify significant influences of the two independent variables and their interaction (treatment, genotype, treatment x genotype interaction). Post test analyses for the planned comparisons (treatment effect, genotype effect)
were performed to assess whether there were significant differences between particular groups.
Post tests were Bonferroni-corrected for multiple comparisons and used the mean square residual (pooled variance) and corresponding degrees of freedom from the two-way ANOVA. A result was considered statistically significant if P < 0.05.
Results
We 
Constitutive hepatic cytochromes P450 and POR
Cyp2d9 encodes a male-specific steroid 16α-hydroxylase and the hepatic expression of this gene is clearly regulated by pulsatile GH in a STAT5b-dependent manner (Udy et al. 1997; Davey et al. 1999; Clodfelter et al. 2006) . TCDD caused a 39% decrease in hepatic CYP2D9 mRNA levels in wild-type mice and this suppression response was not observed in Ahr -/-mice ( Fig. 2A) . In vehicle-treated mice, the basal expression of CYP2D9 mRNA was 2.6-fold higher in wild-type mice compared to Ahr -/-mice ( Fig. 2A) .
Cyp3a11 encodes the most abundant CYP3A subfamily protein in the liver of male mice (Yanagimoto et al. 1997 ) and the expression of this gene is sex-independent and GH-independent in males (Sakuma et al. 2002; Jarukamjorn et al. 2006) . We showed previously that MC treatment caused a dramatic decrease in mouse hepatic CYP3A11 content, particularly at the protein level (Lee et al. 2006) . TCDD caused a 76% decrease in hepatic CYP3A11 mRNA levels in wild-type mice and this suppression response was not observed in Ahr -/-mice ( Fig. 2B ).
In vehicle-treated mice, the basal expression of CYP3A11 mRNA was 4.5-fold higher in Ahr -/-mice compared to wild-type mice (Fig. 2B ).
The flavoprotein POR is the obligate electron-transfer partner protein for all reactions catalyzed by microsomal P450s. Our previous work showed that mouse hepatic POR catalytic activity was increased by up to 33% following MC treatment (Lee et al. 2006) . POR mRNA levels were increased by 55% following TCDD treatment in wild-type mice and this small magnitude induction response was not see in Ahr -/-mice ( Fig. 2C ). In vehicle-treated mice, the basal expression of POR mRNA was 3.1-fold higher in Ahr -/-mice compared to wild-type mice (Fig. 2C ).
Hepatic inflammatory markers
Down-regulated expression of constitutive hepatic P450s often occurs in response to inflammatory conditions (Riddick et al. 2004; Morgan et al. 2008) . Since TCDD treatment in wild-type mice suppressed hepatic mRNA levels for both CYP2D9 and CYP3A11, we checked if TCDD increased expression of two established hepatic inflammatory markers: SAP, a hallmark reactant in the acute phase response to inflammation in mice (Charles et al. 2006) , and SOCS3, an important feedback inhibitor of hepatic cytokine signaling known to be induced by pro-inflammatory cytokines including interleukin-6 (IL-6) (Yang et al. 2005) . We found no evidence for induction of hepatic SAP mRNA levels ( Fig. 3A ) or SOCS3 mRNA levels (Fig. 3B) by TCDD at the 19-h time-point examined. In fact, TCDD treatment decreased SAP mRNA levels by 56% in wild-type mice and by 33% in Ahr -/-mice (Fig. 3A) . In vehicle-treated mice, the basal expression of SAP mRNA was 2.4-fold higher in Ahr -/-mice compared to wild-type mice (Fig. 3A) . Hepatic SOCS3 mRNA levels were not influenced by TCDD treatment or Ahr genotype (Fig. 3B) .
Components of the hepatic GHR-JAK2-STAT5b signal transduction pathway
To determine if suppression of Cyp2d9 by TCDD may be related to disruption of hepatic GH signaling, we measured mRNA levels for the key components in the GHR-JAK2-STAT5b pathway known to control the male-specific hepatic expression of this P450. In wild-type mice, but not Ahr -/-mice, TCDD decreased hepatic mRNA levels for GHR, JAK2 and STAT5a/b by 38%, 53% and 25%, respectively (Fig. 4) . In vehicle-treated mice, the basal mRNA levels for GHR, JAK2 and STAT5a/b did not differ between wild-type and Ahr -/-mice (Fig. 4 ).
Other hepatic STAT5b target genes
Disruption of the hepatic GHR-JAK2-STAT5b signal transduction cascade by TCDD could result in suppression of STAT5b target genes in addition to Cyp2d9. CIS is induced by
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GH via a STAT5b-dependent transcriptional mechanism and plays a role in negative feedback inhibition of GH signaling (Landsman and Waxman 2005) . MUP2 belongs to the family of α2-microglobulin-related liver secretory proteins and is a significant protein component of mouse urine; pulsatile GH signaling via a STAT5b-dependent mechanism confers male-predominant expression of MUP2 (Udy et al. 1997) . Hepatic CIS mRNA levels were not influenced by TCDD treatment or Ahr genotype (Fig. 5A) (Shimada et al. 2002; Tijet et al. 2006 that some, but not all, hepatic genes regulated by the GHR-JAK2-STAT5b pathway may be targeted for suppression by TCDD. It is important to point out that our measurements of CIS mRNA levels were characterized by wide inter-animal variability that may have compromised our ability to discern an effect of TCDD.
Two previous studies (Nukaya et al. 2004; Lee et al. 2006) showed that MC decreases mRNA levels encoding key GH signaling components and that this can result in compromised binding of STAT5a/b to DNA response elements (Nukaya et al. 2004 ). Our current work shows that TCDD down-regulates hepatic GHR, JAK2, and STAT5a/b mRNA levels in an AHRdependent manner. A similar result was reported in the original microarray study for GHR In conclusion, acute exposure to a high dose of TCDD suppresses mouse hepatic Cyp2d9
and Mup2, two genes regulated by pulsatile GH in a STAT5b-dependent manner, and these responses are accompanied by decreased mRNA levels for key components of the GHR-JAK2-STAT5b signaling cascade. These actions of TCDD are AHR-dependent and not accompanied by induction of selected hepatic inflammatory markers. Combined with previous work using MC as a readily metabolized AHR agonist (Nukaya et al. 2004; Lee et al. 2006) , this study using TCDD and the Ahr -/-mouse model suggests that AHR activation per se leads to dysregulation of hepatic GH signaling components and suppression of some, but not all, STAT5b target genes. TCDD diffuses through the plasma membrane and may disrupt this signaling pathway via AHRdependent or AHR-independent mechanisms. We also assessed whether TCDD's effects were accompanied by induction of two hepatic inflammatory markers (SAP and SOCS3). analyzed initially using a randomized-design two-way ANOVA and the P values for the main effects are reported here: CYP2D9 (treatment, P = 0.1177; genotype, P = 0.0022; interaction, P = 0.0597), CYP3A11 (treatment, P = 0.0031; genotype, P < 0.0001; interaction, P = 0.7639), and POR (treatment, P = 0.4288; genotype, P < 0.0001; interaction, P = 0.0298). Planned comparisons to identify significant differences between particular groups utilized a post test Bonferroni-corrected for multiple comparisons. *, significantly different (P < 0.05) from genotype-matched vehicle control mice; †, significantly different (P < 0.05) from treatmentmatched wild-type mice. CIS (treatment, P = 0.2762; genotype, P = 0.5544; interaction, P = 0.7782), and MUP2
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(treatment, P = 0.0286; genotype, P < 0.0001; interaction, P = 0.0036). Planned comparisons to identify significant differences between particular groups utilized a post test Bonferronicorrected for multiple comparisons. *, significantly different (P < 0.05) from genotype-matched vehicle control mice; †, significantly different (P < 0.05) from treatment-matched wild-type mice. 
